The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia

Clinical Trial ID NCT04273529

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04273529

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 6.59
2 Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies. Clin Exp Immunol 2009 0.76
3 Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice. Inflammation 2014 0.75
Next 100